Teleflex (NYSE:TFX) shares surged 9.74% in pre-market trading on Thursday following the release of its impressive second-quarter financial results and an upward revision of its full-year 2025 guidance. The medical technology company's performance exceeded analyst expectations, demonstrating resilience and growth across key metrics.

For the second quarter of 2025, Teleflex reported adjusted earnings per share (EPS) of $3.73, significantly beating the analyst consensus estimate of $3.36 by 11.04%. This represents a 9.06% increase compared to the $3.42 per share reported in the same period last year. The company's quarterly sales also outperformed expectations, reaching $780.889 million, surpassing the analyst consensus estimate of $771.477 million by 1.22%. This figure marks a 4.16% year-over-year increase from $749.691 million.

In light of its strong performance, Teleflex has raised its full-year 2025 outlook. The company now projects annual revenue growth of 9-10% and has increased its earnings guidance. The new EPS forecast for continuing operations is set at $6.73-$7.13, while the adjusted EPS for continuing operations is expected to be in the range of $13.90-$14.30. This positive revision in guidance suggests management's confidence in the company's continued growth trajectory and operational efficiency, which has clearly resonated with investors, as reflected in the pre-market stock surge.